Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines
Introduction Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both mucosal and systemic immune responses have garnered increasing attention. However, human physiological characteristics pose significant challenges in the evaluation of mucosal immunity, which direc...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2326094 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141447735083008 |
|---|---|
| author | Xuanxuan Zhang Jialu Zhang Si Chen Qian He Yu Bai Jianyang Liu Zhongfang Wang Zhenglun Liang Ling Chen Qunying Mao Miao Xu |
| author_facet | Xuanxuan Zhang Jialu Zhang Si Chen Qian He Yu Bai Jianyang Liu Zhongfang Wang Zhenglun Liang Ling Chen Qunying Mao Miao Xu |
| author_sort | Xuanxuan Zhang |
| collection | DOAJ |
| description | Introduction Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both mucosal and systemic immune responses have garnered increasing attention. However, human physiological characteristics pose significant challenges in the evaluation of mucosal immunity, which directly impedes the development and application of respiratory mucosal vaccines.Areas Covered This study summarizes the characteristics of immune responses in the respiratory mucosa and reviews the current status and challenges in evaluating immune response to respiratory mucosal vaccines.Expert Opinion Secretory Immunoglobulin A (S-IgA) is a major effector molecule at mucosal sites and a commonly used indicator for evaluating respiratory mucosal vaccines. However, the unique physiological structure of the respiratory tract pose significant challenges for the clinical collection and detection of S-IgA. Therefore, it is imperative to develop a sampling method with high collection efficiency and acceptance, a sensitive detection method, reference materials for mucosal antibodies, and to establish a threshold for S-IgA that correlates with clinical protection. Sample collection is even more challenging when evaluating mucosal cell immunity. Therefore, a mucosal cell sampling method with high operability and high tolerance should be established. Targets of the circulatory system capable of reflecting mucosal cellular immunity should also be explored. |
| format | Article |
| id | doaj-art-59640d3b85b14c95b034c26e101fbe2a |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-59640d3b85b14c95b034c26e101fbe2a2024-12-04T09:49:47ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123136237010.1080/14760584.2024.2326094Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccinesXuanxuan Zhang0Jialu Zhang1Si Chen2Qian He3Yu Bai4Jianyang Liu5Zhongfang Wang6Zhenglun Liang7Ling Chen8Qunying Mao9Miao Xu10State Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, ChinaDrug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaDrug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaDrug and Vaccine Research Center, Guangzhou National Laboratory, Guangzhou, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaState Key Laboratory of Drug Regulatory Science, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, ChinaIntroduction Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both mucosal and systemic immune responses have garnered increasing attention. However, human physiological characteristics pose significant challenges in the evaluation of mucosal immunity, which directly impedes the development and application of respiratory mucosal vaccines.Areas Covered This study summarizes the characteristics of immune responses in the respiratory mucosa and reviews the current status and challenges in evaluating immune response to respiratory mucosal vaccines.Expert Opinion Secretory Immunoglobulin A (S-IgA) is a major effector molecule at mucosal sites and a commonly used indicator for evaluating respiratory mucosal vaccines. However, the unique physiological structure of the respiratory tract pose significant challenges for the clinical collection and detection of S-IgA. Therefore, it is imperative to develop a sampling method with high collection efficiency and acceptance, a sensitive detection method, reference materials for mucosal antibodies, and to establish a threshold for S-IgA that correlates with clinical protection. Sample collection is even more challenging when evaluating mucosal cell immunity. Therefore, a mucosal cell sampling method with high operability and high tolerance should be established. Targets of the circulatory system capable of reflecting mucosal cellular immunity should also be explored.https://www.tandfonline.com/doi/10.1080/14760584.2024.2326094Respiratory tractmucosal vaccinemucosal antibodymucosal cellular immunityclinical evaluation |
| spellingShingle | Xuanxuan Zhang Jialu Zhang Si Chen Qian He Yu Bai Jianyang Liu Zhongfang Wang Zhenglun Liang Ling Chen Qunying Mao Miao Xu Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines Expert Review of Vaccines Respiratory tract mucosal vaccine mucosal antibody mucosal cellular immunity clinical evaluation |
| title | Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| title_full | Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| title_fullStr | Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| title_full_unstemmed | Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| title_short | Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| title_sort | progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines |
| topic | Respiratory tract mucosal vaccine mucosal antibody mucosal cellular immunity clinical evaluation |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2326094 |
| work_keys_str_mv | AT xuanxuanzhang progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT jialuzhang progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT sichen progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT qianhe progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT yubai progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT jianyangliu progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT zhongfangwang progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT zhenglunliang progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT lingchen progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT qunyingmao progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines AT miaoxu progressandchallengesintheclinicalevaluationofimmuneresponsestorespiratorymucosalvaccines |